Non-invasive robotics platform and sonic beam therapy developer HistoSonics announced today that it closed a Series C-1 financing worth $40 million. Yonjin Venture led the oversubscribed funding round, while Varian Medical Systems, Johnson & Johnson Innovation, Venture Investors, Lumira Ventures, State of Wisconsin Investment Board and more participated as well, according to a news release. […]
HistoSonics said today that its non-invasive robotics platform and novel sonic beam cancer therapy successfully destroyed 11 tumors in eight patients during its first clinical trial. The results were presented this week at the 2019 Society of Interventional Oncology (SIO) Annual Meeting in Boston. The meeting also included preclinical presentations of what HistoSonics termed promising […]
HistoSonics said today that it closed a $54 million Series C round led by Varian Medical (NYSE:VAR) that included a contribution from Johnson & Johnson (NYSE:JNJ). The Ann Arbor, Mich.-based company, which is developing an image-guided, robotically assisted platform using non-invasive and non-thermal technologies, said Lumira Ventures, Venture Investors, the State of Wisconsin Investment Board and […]
HistoSonics has raised $4.8 million in a new debt and warrants round of financing, according to a recently posted SEC filing. HistoSonics is developing an image-guided, robotically assisted platform therapy using non-invasive and non-thermal technologies, according to the company’s website. Money in the round came from 20 anonymous investors, with the first sale noted on […]
Relievant Medsystems said it named former Cameron Medical chief Kevin Hykes to be its new CEO, effective immediately. Hykes, who led Cameron Health to a $1.35 billion buyout in 2012 by Boston Scientific (NYSE:BSX), replaced Alex DiNello, who was named COO, Relievant said. Relievant makes the Intracept device for treating lower back pain. Hykes was most recently […]
Michigan medical device maker HistoSonics is creeping toward the close of a $14.22 million funding round in support of its non-invasive tissue ablation technology.
The company has raised about $14.17 million so far from 13 unnamed investors, through sales of equity, options, warrants and other rights to acquire securities, according to an SEC filing dated May 16.
HistoSonics Inc. brought former Food & Drug Administration commissioner Dr. Andrew von Eschenbach onto its board yesterday.
The ex-commissioner’s experience as a surgeon, urological oncologist and healthcare administrator made him a good fit, said the Ann Arbor, Mich.-based company, which is developing a treatment for urological cancer.
CEO Tom Davison said "[Dr. von Eschenbach’s] commitment to safe and effective healthcare and especially cancer therapy aligns precisely with HistoSonics’ vision and long term strategy," in a prepared statement.